Mettler-Toledo International Inc. (MTD)
Mettler-Toledo makes high-precision weighing instruments and analytical tools used by scientists and manufacturers to ensure accuracy in their work.
Is Mettler-Toledo International Inc. a good stock for a UK beginner?
The honest version: Mettler-Toledo makes high-precision weighing instruments and analytical tools used by scientists and manufacturers to ensure accuracy in their work.
Over about 2 years to 2026-07-31. This is the share price only; any dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
Expansion into new emerging markets for laboratory automation.
Long-term decline in global pharmaceutical research investment.
What does Mettler-Toledo International Inc. do?
Think of Mettler-Toledo as the gold standard for precision measurement; they provide the scales and laboratory equipment that pharmaceutical companies and food producers rely on to get their formulas exactly right. Selling these high-end devices earns the bulk of the money, along with the ongoing service and software needed to keep them calibrated. Their growth tracks how much their customers, often big research labs, are willing to spend on new equipment.
On our factor screen it looks strongest on momentum and quality, and weakest on income.
- !Pays no dividend - the whole return rides on the share price
- ✓Growing - revenue up about 4% over the year
- ✓Very profitable - turns about 22% of sales into profit
- !High P/E of 32 - big growth is already priced in
- !Carries a lot of debt - roughly 164.7x its equity
- Strong profit margins showing a healthy business model
- Essential role in highly regulated industries like medicine and food
- High barrier to entry due to the precision required in their products
- Income screens low (16/100)
- Economic downturns leading to cuts in research and development budgets
- Increased competition from cheaper, lower-precision alternatives
- Supply chain disruptions affecting the delivery of complex components
What do Mettler-Toledo International Inc.'s numbers mean?
How much money does Mettler-Toledo International Inc. make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Does Mettler-Toledo International Inc. pay a dividend?
No - Mettler-Toledo International Inc. doesn't currently pay a dividend, so the whole return would rest on the share price. Plenty of growing companies reinvest their profits instead of paying them out - neither approach is better or worse, they're just different.
When does Mettler-Toledo International Inc. report earnings, and how did recent quarters go?
Mettler-Toledo International Inc. is next scheduled to report on about 2026-11-05 - dates can move, and we don't predict results; this just tells you when to look.
Each quarter a company reports its results against what analysts expected. ‘Beating’ or ‘missing’ is about that expectation, not whether the business is doing well in absolute terms.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-07-30 | $10.81 | $11.46 | Beat +6% |
| 2026-05-07 | $8.71 | $8.91 | Beat +2% |
| 2026-02-05 | $12.81 | $13.36 | Beat +4% |
| 2025-11-06 | $10.66 | $11.15 | Beat +5% |
| 2025-07-31 | $9.60 | $10.09 | Beat +5% |
| 2025-05-01 | $7.88 | $8.19 | Beat +4% |
Across the last 6 quarters here, Mettler-Toledo International Inc. came in ahead of what analysts expected 6 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Reported vs expected earnings per share (EPS) from published results; the expectation is the analyst consensus, not our view. Report dates are estimates that can move.
More in Healthcare
Eli Lilly
West Pharmaceutical Services, Inc.
Incyte Corporation
The Cigna Group
Zimmer Biomet Holdings, Inc.
Moderna, Inc.
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.What are the scenarios for Mettler-Toledo International Inc.?
An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.
What are the pros and cons of Mettler-Toledo International Inc.?
How many points the write-up makes each way — a balance check, not a score or verdict.
- Strong profit margins showing a healthy business model
- Essential role in highly regulated industries like medicine and food
- High barrier to entry due to the precision required in their products
- No dividend payments for those looking for regular income
- High valuation compared to some other industrial companies
- Relies heavily on the spending habits of large research institutions
- Economic downturns leading to cuts in research and development budgets
- Increased competition from cheaper, lower-precision alternatives
- Supply chain disruptions affecting the delivery of complex components
The write-up's own warning lights — if these start happening, the case above changes.
- A significant, sustained drop in global pharmaceutical research spending
- A major technological breakthrough that makes their precision scales obsolete
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-01 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.